Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
4/13/26 Revolution Medicines (RVMD) daraxonrasib for Pancreatic Cancer Subscribers Only Subscribers Only Subscribers Only
4/11/26 Viatris (VTRS) Ryzumvi for Presbyopia Subscribers Only Subscribers Only Subscribers Only
4/7/26 NervGen Pharma (NGEN) NVG-291 for Spinal Cord Injury (SCI) Subscribers Only Subscribers Only Subscribers Only
4/2/26 Immunovant (IMVT) batoclimab for Thyroid Eye Disease (TED) Subscribers Only Subscribers Only Subscribers Only
4/2/26 AstraZeneca (AZN) Imfinzi for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
06/30/2022 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results
10/22/2023 Subscribers Only Subscribers Only Trial Data - Updated Results